Development and Successful Treatment of Spinal Mixed Histiocytosis in an Elderly Woman following Two Relapses of BRAF-mutated Unifocal Skull Langerhans Cell Histiocytosis

Read full text Summarise with VIRAT
Authors: Tsuneyoshi Hamada, Miyako Kobayashi, Ayaka Fukui, Naoki Nakajima, Naoyuki Anzai, Shinsaku Imashuku
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Development of mixed histiocytosis (Langerhans cell histiocytosis (LCH))/Erdheim–Chester disease (ECD)) after treatment in patients with an initial skull LCH lesion has not been well recognized. An elderly woman initially developed LCH at the left temporal bone, preceded by polyuria and polydipsia five years earlier; the lesion was surgically removed. Two years thereafter, she experienced her first LCH relapse with a right parietal skull lesion, in which a BRAF V600E mutation was confirmed, and chemotherapy was initiated. After a second LCH relapse involving the left parietal bone, the patient presented with a third relapse at the L2 vertebra. This lesion was pathologically diagnosed as mixed histiocytosis (LCH/ECD), resulting in refractoriness to conventional chemotherapy, and was successfully treated with targeted therapy using BRAF and MEK inhibitors. Spinal mixed histiocytosis (LCH/ECD) may develop following relapses of skull LCH after chemotherapy, for which targeted therapy could be effective.

Fields of Study & Subjects

Histiocytic Disorders and Treatments Bone Tumor Diagnosis and Treatments Vascular Malformations and Hemangiomas

Publication details

Journal / source
Oncology Advances
Volume
4
Issue
1
Pages
e00030–e00030
Publication date
23 March 2026
Language
EN